Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

BriaCell Therapeutics Inc. V.ACP

Sector: Healthcare | Sub-Sector: Biotechnology
Primary Symbol: V.BCT
Alternate Symbol(s):  ANCCF

BriaCell Therapeutics Inc is a breast cancer immunotherapy biotech. It has developed a patented whole-cell vaccine, cancer immunotherapy technology called the 'BriaVax' vaccine.
Price: $0.22 Volume: 570,919
Change: +$0.04 % Change: +22.22%
Day High/Low: 0.22/0.175 52 Week High/Low: 0.30/0.14
Last Traded: March 27, 2015 11:59 Transaction Volume: 5000
Open: 0.185 Previous Close: 0.18
Bid: 0.22 Ask: 0.235
Bid Size: 42500 Ask Size: 15000
Market Cap: 18.6m Shares Out: 84.5m
PE Ratio: N/A Dividend Yield: N/A

Latest Bullboard Posts

  • RE:owned by mang.

    0 stars

    https://canadianinsider.com/node/7?menu_tickersearch=BCT%20%7C%20BriaCell%20Therapeutics ooks like a lot imo. Ceo has 14million. Another...

    2 stars


  • owned by mang.

    0 stars

    Does anybody know how many shares are owned by insiders.Thanks.

    2.5 stars


  • BRIAVAX VACCINE! Game changer?

    5 stars

    BRIACELL BACKGROUND BriaCell is a breast cancer immunotherapy biotechnology company. Immunotherapies have come to the forefront of the...

    2 stars


  • Investors are Starting to see bct.v potential!

    5 stars

    As pinkD stated below. This is hidden gem. Their vaccine is 10 years in the making and only went public 3 months ago.... This product...

    2 stars


  • News Imminent?

    5 stars

    Big volume today. The majority of the shares traded during the last 2 hours with buying coming from multiple sources. Makes me wonder if...

    2.5 stars